Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 4Phase 3 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 2Stomach Neoplasms 1Recurrence 1Lung Diseases 1Adenocarcinoma Of Esophagus 1

Interventions

Carboplatin 190Cisplatin 156Pemetrexed 151Paclitaxel 127Docetaxel 109pembrolizumab 87Gemcitabine 73Erlotinib Hydrochloride 44Radiotherapy 39Vinorelbine 35Gefitinib 34durvalumab 31Bevacizumab 28Nivolumab 26Drug Therapy 23atezolizumab 22osimertinib 19130-nm albumin-bound paclitaxel 19tislelizumab 16Crizotinib 16Radiosurgery 15Etoposide 14Surgical Procedures, Operative 11Afatinib 11Ipilimumab 10icotinib 9aumolertinib 9Albumin-Bound Paclitaxel 9Specimen Handling 8Observation 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Non-Small-Cell Lung × zimberelimab × Clear all
NCT06431633 2026-05-18

ARIAN

Fundación GECP

Phase 3 Recruiting
129 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Diseases

NCT05502237 2026-01-30

STAR-121

Gilead Sciences

Phase 3 Active not recruiting
1,021 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡